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The Journal of Immunology
Mapping the Binding Site of a Cross-Reactive Plasmodium
falciparum PfEMP1 Monoclonal Antibody Inhibitory of
ICAM-1 Binding
Frank Lennartz,*,1 Anja Bengtsson,†,‡,1 Rebecca W. Olsen,†,‡,1 Louise Joergensen,†,‡
Alan Brown,x Louise Remy,{ Petr Man,‖,# Eric Forest,{ Lea K. Barfod,†,‡
Yvonne Adams,†,‡ Matthew K. Higgins,* and Anja T. R. Jensen†,‡
The virulence of Plasmodium falciparum is linked to the ability of infected erythrocytes (IE) to adhere to the vascular endothelium,
mediated by P. falciparum erythrocyte membrane protein 1 (PfEMP1). In this article, we report the functional characterization of an
mAb that recognizes a panel of PfEMP1s and inhibits ICAM-1 binding. The 24E9 mouse mAb was raised against PFD1235w
DBLb3_D4, a domain from the group A PfEMP1s associated with severe malaria. 24E9 recognizes native PfEMP1 expressed on
the IE surface and shows cross-reactivity with and cross-inhibition of the ICAM-1 binding capacity of domain cassette 4 PfEMP1s.
24E9 Fab fragments bind DBLb3_D4 with nanomolar affinity and inhibit ICAM-1 binding of domain cassette 4–expressing IE. The
antigenic regions targeted by 24E9 Fab were identified by hydrogen/deuterium exchange mass spectrometry and revealed three
discrete peptides that are solvent protected in the complex. When mapped onto a homology model of DBLb3_D4, these cluster to
a defined, surface-exposed region on the convex surface of DBLb3_D4. Mutagenesis confirmed that the site most strongly protected is
necessary for 24E9 binding, which is consistent with a low-resolution structure of the DBLb3_D4::24E9 Fab complex derived from
small-angle x-ray scattering. The convex surface of DBLb3_D4 has previously been shown to contain the ICAM-1 binding site of
DBLb domains, suggesting that the mAb acts by occluding the ICAM-1 binding surface. Conserved epitopes, such as those targeted
by 24E9, are promising candidates for the inclusion in a vaccine interfering with ICAM-1–specific adhesion of group A PfEMP1
expressed by P. falciparum IE during severe malaria. The Journal of Immunology, 2015, 195: 3273–3283.
H
uman malaria caused by Plasmodium falciparum para-
sites remains a serious health problem. In 2013, an es-
timated 198 million cases of malaria resulted in 584,000
deaths, mostly in sub-Saharan Africa (1). The majority of deaths
occurred in children ,5 y of age.
Parasite virulence is linked to the ability of infected erythrocytes
(IE) to adhere to the inside of host blood vessels, leading to in-
flammation, tissue obstruction, and organ dysfunction (2). IE ad-
hesion is mediated by the surface expression of P. falciparum
erythrocyte membrane protein 1 (PfEMP1) proteins, which are
able to bind to various host receptors present on the endothelium.
The multidomain PfEMP1 proteins are encoded by ∼60 diver-
gent var genes and consist of Duffy-binding–like (DBL) and
cysteine-rich interdomain region protein domains (3), which can
be divided into several major types (a, b, g, etc.) and subtypes
based on sequence similarities (4, 5). DBL domains generally
contain three subdomains, which fold together to form a con-
served a-helical core with loop insertions of variable sequence
and length. Specific DBL and cysteine-rich interdomain region
domains group together to form domain cassette (DC) families
that are found across parasite isolates (5).
A frequently described PfEMP1 receptor is ICAM-1, and
binding of IE to ICAM-1 during infection is linked to the devel-
opment of symptoms of severe malaria, such as cerebral malaria
(6–8). ICAM-1 is a membrane-bound protein with five extracel-
lular domains (D1-D5) and is expressed by endothelial cells and
leukocytes. ICAM-1 mediates leukocyte adhesion and migration
to inflamed sites by binding to LFA-1 and Mac-1 (9, 10).
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Surface expression of the recently identified DC4 containing
PfEMP1s leads to ICAM-1–specific adhesion of IE, which is
mediated by the DBLb3_D4 PfEMP1 domain (11, 12) and appears
to be involved in the pathogenesis of severe disease (13). Naturally
acquired Abs against DC4 DBLb3_D4 are cross-reactive and cross-
inhibitory of ICAM-1 binding across members of DC4 and other
DC types (12), suggesting that the DC4 DBLb3 domains are at-
tractive vaccine candidates.
Although no crystal structure exists currently for a DBLb::
ICAM-1 complex, this interaction has been studied in a number
of different ways. Studies with truncated or mutated ICAM-1
constructs show that the binding site for DBLb domains locates
to the D1 domain of ICAM-1, and experiments with truncated
and chimeric proteins have mapped the ICAM-1 binding site to
the C-terminal end of DBLb (14–17). In addition, ICAM-1
binding is gained when replacing the C-terminal subdomain of
an ICAM-1 nonbinding DBLb3 with that of the ICAM-1 binding
PFD1235w DBLb3_D4 (12). Homology modeling (18) and small-
angle x-ray scattering (SAXS) (19), together with mutagenesis
studies (20), further suggest that the interaction surface is on
the convex surface of the DBLb domain. However, the exact
amino acids involved in DBLb binding to ICAM-1 are yet to be
determined.
The identification of DBLb region(s) targeted by protective
Abs and a detailed mapping of ICAM-1 binding epitopes will be
an essential step toward designing a PfEMP1-based vaccine po-
tentially protective against malaria. Using modern methods for the
characterization of Ab–Ag complexes, such as hydrogen/deuterium
exchange mass spectrometry (HDX MS), surface plasmon reso-
nance (SPR), and SAXS, we characterized an mAb (24E9) that
binds to the convex surface of DC4 DBLb3_D4 domains and
interferes with the DBLb::ICAM-1 interaction. We show that 24E9
mAb targets epitopes conserved between DC4 DBLb domains from
genetically distant parasite isolates and inhibits ICAM-1 binding of
IE by blocking the predicted ICAM-1 binding site on DBLb. This
provides important knowledge for choosing components for a vac-
cine aimed at preventing PfEMP1-mediated adhesion of IE during
severe malaria.
Materials and Methods
Recombinant protein expression and purification
Full-length, wild-type PFD1235w DBLb3_D4 was subcloned into a mod-
ified pET15b vector and expressed as an N-terminal, hexahistidine-tagged
protein in Escherichia coli SHuffle 3030 cells (New England Biolabs) for
16 h at 25˚C. The cells were pelleted, washed, and lysed, and DBLb3_D4
was purified using Ni-NTA-Sepharose (QIAGEN). The hexahistidine-tag
was removed by overnight cleavage at 4˚C using Tobacco etch virus pro-
tease. Tobacco etch virus protease and uncleaved protein were removed
by reverse immobilized-metal affinity chromatography, and DBLb3_D4
was further purified by size exclusion chromatography using a Superdex 75
16/60 column (GE Healthcare).
PFD1235w DBLb3_D4 protein used for mouse immunization to
generate hybridomas was subjected to an additional purification step.
DBLb3_D4 was allowed to bind to ICAM-1_D1-D5-Fc coupled to a
HiTrap NHS-activated HP column (GE Healthcare). Bound DBLb3_D4
was eluted from ICAM-1 on the column and buffer exchanged into PBS.
For generation of DBLb3_D4 mutants, a set of 59 phosphorylated pri-
mers that included the coding sequence for the P2b or P3a regions of
DBLb3_D5 was used to amplify the DBLb3_D4-encoding pEt15b vector
by PCR. The PCR products were circularized by blunt-end ligation using
T4 ligase (Life Technologies), and the mutants were expressed and purified
as described for DBLb3_D4.
ICAM-1 domains 1–5 (D1–D5) combined with the Fc region of human
IgG1 (ICAM-1-Fc) was cloned, expressed, and purified as described pre-
viously (21). ICAM-1_D1-D2 was expressed in COS-7 cells and purified
as described previously (19). ICAM-1_D1 was expressed and purified from
E. coli BL21(DE3) as described previously (22).
CD spectroscopy
Far-UV CD spectroscopy experiments were carried out with a J-815
Spectropolarimeter (Jasco) equipped with a computer-controlled Peltier
temperature control unit. All samples were dialyzed into 10 mM sodium
phosphate buffer, 150 mM NaF, pH 7.2, and measurements were taken at
a protein concentration of 0.1 mg/ml using a 1 mM path cell. Spectra were
acquired at 20˚C at wavelengths between 195 and 260 nm. For thermal
unfolding, the temperature was raised from 20˚ to 95˚C in 0.5˚C incre-
ments, and spectra were recorded between 200 and 250 nm wavelength.
Hybridoma production
24E9 hybridomas were produced according to standard protocols (23).
One CB6FI mouse (Harlan) was immunized s.c. with 30 mg PFD1235w
DBLb3_D4 in CFA (Sigma-Aldrich) followed by two additional boosters
of 15 mg protein in IFA (Sigma-Aldrich). A final i.v. boost of 15 mg protein
in PBS was given 3 d before the mouse was sacrificed and the spleen was
taken out. Single spleen B lymphocytes were made from the whole spleen
and fused to SP2/0-AG14 Myeloma cells (ATCC) in a 1:2 ratio using
polyethylene glycol 4000. Spleen and myeloma cell mixture was diluted in
80 ml cell media (RPMI, 20% FBS, glutamine, penicillin/streptomycin)
containing HAT media supplement (Sigma-Aldrich) to select for fused
cells. A total of 100 ml/well was added to eight deep, flat-bottom, 96-well
plates (Fisher Scientific) containing peritoneal macrophages from two
BALB/C mice (Taconic) serving as feeder cells. Cells were grown for 1 wk
at 37˚C, 5% CO2 before changing the cell supernatant to cell media sup-
plemented with HT media supplement (hypoxanthine and thymidine; Sigma-
Aldrich). Two weeks after fusion, wells with growing cells were identified
under a microscope and the cells were moved into fresh 96-well plates. After
1 wk, undiluted cell supernatant from each well was tested for the presence
of DBLb3_D4-reactive Abs using ELISA. To obtain true monoclonal
hybridomas, we cloned cells from positive wells by limiting dilution. All
animal procedures were approved by the Danish National Committee
(Dyreforsøgstilsynet) in agreement with permit no. 2008/561-1498.
mAb purification
24E9 monoclonal hybridomas were expanded and seeded at ∼10% con-
fluency in 175-cm2 cell flasks containing 70 ml cell media [RPMI, 10%
low IgG FBS (Lonza), HT media supplement (Sigma-Aldrich), glutamine,
penicillin/streptomycin]. After incubation for 1 wk at 37˚C, 5% CO2
cell supernatant was centrifuged, sterile-filtered, and buffer-exchanged
into PBS before purifying mAb using a HiTrap protein G column (GE
Healthcare) according to the manufacturer’s instructions.
IgG subtyping
The IgG subtype and L chain class of 24E9 mAb were determined using
an IsoQuick Kit for Mouse Monoclonal Isotyping (Sigma) according to
the manufacturer’s instructions.
Fab fragmentation
Purified 24E9 mAb was buffer-exchanged into cleavage buffer (0.1 M
sodium phosphate pH 6.4, 0.3 M NaCl, 2 mM EDTA, 5 mM L-cysteine,
1.5 mM 2-ME) and concentrated to 1 mg/ml. Papain-agarose (Sigma-
Aldrich) was added in a 20:1 ratio and incubated overnight at 37˚C.
Papain-agarose was removed by centrifugation, and the Fc portion and
uncleaved mAb were removed from the supernatant by purification on
a protein A column (GE Healthcare). Fab fragments in the flow-through
were further purified by size exclusion chromatography.
Western blot
Purified 24E9 mAb was tested for reactivity against reduced (+DTT)
and nonreduced (2DTT) PFD1235w DBLb3_D4. Purified PFD1235w
DBLb3_D4 and PFD1235w DBLb3_D5 (control; 0.5 mg) were separated
by SDS-PAGE under both conditions on a NuPAGE Novex 4–12% Bis-
Tris gel in MOPS SDS Running buffer (Invitrogen) and subsequently
blotted onto a Hybond-C Extra NC membrane (GE Healthcare). The
membrane was blocked using 2.5% skimmed milk in dilution buffer (PBS,
1% BSA). The 24E9 mAb was diluted to 10 mg/ml in dilution buffer and
added to the membrane. Bound 24E9 mAb was detected by anti-mouse
IgG (P260; Dako) 1:1000 in dilution buffer using a chemiluminescent
detection kit (Thermo Scientific).
ELISA
Hybridoma screening. Hybridoma cell supernatants were screened for
PFD1235w DBLb3_D4-reactive Abs using ELISA. Duplicate wells of
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MaxiSorp microtiter plates (Nunc) were coated with DBLb3_D4 (50 ml;
1 mg/ml; 0.1 M glycine/HCl buffer pH 2.75; overnight; 4˚C) and blocked
with blocking buffer (PBS, 0.5 M NaCl, 1% Triton X-100, 1% BSA, pH
7.2). A total of 100 ml undiluted cell supernatant was added (1 h; room
temperature). The plates were washed in PBS + 1% Triton X-100, and
bound Ab was detected with an anti-mouse Ig-HRP (Dako; 1:3000 in
blocking buffer). After 1 h of incubation, plates were developed using OPD
tablets (Dako) according to the manufacturer’s instructions. The OD value
was read at 490 nm using a VERSAmax microplate reader (Molecular
Devices) and Softmax Pro v4.7.1.
mAb reactivity. Microtiter plates were coated with 50 ml, 2 mg/ml
recombinant proteins in glycine/HCl buffer and blocked with blocking
buffer. 24E9 mAb (50 ml; 3-fold dilutions starting at 10 mg/ml; 1 h; room
temperature) was added, and washing was performed as described above.
Bound Ab was detected with anti-mouse Ig-HRP (Dako; 1:3000 in
blocking buffer; 1 h; room temperature).
Reducing ELISA. Microtiter plates were coated (50 ml; 2-fold dilutions
starting at 64 mg/ml; glycine/HCl buffer; overnight; 4˚C) with 24E9 mAb
or the PFD1235w DBLg-specific AB01 mAb (24) and blocked with PBS +
1% BSA. Plates were washed in PBS and PFD1235w DBLb3_D4 or
PFD1235w DBLg (50 ml; 2 mg/ml; PBS 6 50 mM DTT; 1 h; room
temperature) were added to the plates coated with 24E9 or AB01, re-
spectively. Bound DBLb3_D4 or DBLg was detected by use of an anti–
penta-His HRP Ab (1:3000 in PBS + 1% BSA; 1 h; room temperature;
QIAGEN). Washing and detection were performed as described above.
ICAM-1 inhibition ELISA. Microtiter plates were coated with recombinant
ICAM-1–Fc (50 ml, 2 mg/ml; glycine/HCl buffer; overnight; 4˚C) and
blocked with blocking buffer. DBLb3_D4 domains (1–16 mg/ml) were
added simultaneously with mAb 24E9 added in 2-fold dilutions ranging
from 0.25 to 32 mg/ml. Mouse IgG (Life Technologies) was added as
control. ICAM-1–bound DBLb3_D4 was detected using anti–penta-His
HRP Ab (1:3000 in blocking buffer; 1 h; room temperature; QIAGEN).
Washing and detection were performed as described above.
Sequencing
The mouse Ig L and H chain variable genes of the 24E9 mAb were se-
quenced to determine the amino acid sequences of the CDRs. cDNA was
made from single 24E9 hybridoma cells using a QIAGENOneStep RT-PCR
Kit with degenerate primers designed to target mouse Ig variable regions
(25). cDNA was amplified using Phusion HF polymerase (New England
Biolabs), and PCR products were sequenced using BigDye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems) according to the man-
ufacturer’s instructions. Sequence data were collected on a 3100-Avant
Genetic Analyzer (Applied Biosystems). The nucleotide sequences of
24E9 CDRs can be retrieved from GenBank using accession numbers
KJ418726 (H chain) and KJ418727 (L chain) (http://www.ncbi.nlm.nih.
gov/genbank).
Malaria parasites and flow-cytometry analysis
The 3D7 P. falciparum clone and one Ghanaian patient isolate (BM057)
were cultured in vitro (26) and were selected for DC4 PfEMP1 IE surface
expression by repeated Ab selection as described previously (12). The
identity of the isolates was routinely verified by genotyping as described
previously (27), and Mycoplasma infection was regularly excluded using
the MycoAlert Mycoplasma Detection Kit (Lonza) according to the
manufacturer’s instructions.
P. falciparum IE were DNA-labeled with ethidium bromide and surface-
labeled with mouse antisera obtained from the immunized mouse used for
hybridoma production (15 ml serum/well), 24E9 mAb (100 mg/ml), or
24E9 Fab fragments (100 mg/ml). Whole Abs were labeled using an FITC-
conjugated secondary anti-mouse IgG (1:100; Vector Labs), and an anti-
mouse F(ab9)2 IgG (1:100; Jackson Immunoresearch) was used to detect
Fab fragments. FITC fluorescence data from ethidium bromide+ cells were
collected on a Cytomics FC 500 MPL flow cytometer (Beckman Coulter)
and analyzed in WinList version 6.0 (Verity Software House).
ICAM-1 adhesion assays under physiological flow conditions
Biochips (Vena8; Cellix) were coated at 4˚C overnight with recombinant
ICAM-1–Fc (50 mg/ml) produced as described previously (21). Channels
[400 3 100 3 20 mm (w 3 d 3 l)] were blocked for 1 h at 37˚C with
PBS + 1% BSA and the chip mounted onto a Leica inverted phase-contrast
microscope. To generate a wall shear stress representing that within mi-
crovasculature (1 dyn/cm2), we connected the biochip to an NE-1002X
microfluidic pump (World Precision Instruments, U.K.). Erythrocytes at 3–
5% parasitemia (1% hematocrit in RPMI 1640 plus 2% normal human
serum) were flowed over the biochip for 5 min. The number of bound IE
per square millimeter for five separate fields was counted at 20 times
magnification, and a minimum of three independent experiments was done
in triplicates.
To inhibit ICAM-1 adhesion, we combined IE with 24E9 mAb (1 3
1021; 1, 10 mg/ml) or Fab fragments of 24E9 (1 3 1023; 1 3 1021;
1 mg/ml) before assaying as described earlier. Mouse IgG (10 mg/ml;
Life Technologies) or mouse IgG Fab fragments (1 mg/ml; Rockland)
were included as negative controls. Specificity of adhesion to recombinant
ICAM-1–Fc was determined by the preincubation of channels with
40 mg/ml anti–ICAM-1 (clone 15.2; AbD Serotec).
SPR
SPR measurements were conducted using a BIAcore T-100 instrument (GE
Healthcare). DBLb3_D4 was diluted into 10 mM acetate buffer, pH 4.0,
and covalently coupled to a CM5 chip (GE Healthcare) by amine coupling
to a density of 400 response units (RU). ICAM-1_D1, ICAM-1_D1-D2,
and mAb 24E9 Fab were prepared in 10 mM HEPES pH 7.2, 150 mM
NaCl, 50 mM EDTA, and 0.05% Tween 20. For each protein, a concen-
tration series (100, 50, 25, 12.5, and 6.25 mg/ml) was flowed over the chip
surface at a flow rate of 45 ml/min with an association time of 120 s and
a dissociation time of 400 s. The signal from an empty flow cell was
subtracted from all measurements. Between runs, the sensor surface was
regenerated with 4 M MgCl2 for 30 s at a flow rate of 30 ml/min for the
24E9 Fab::DBLb3_D4 interaction, or 5 mM NaOH for 10 s at a flow rate
of 30 ml/min for the ICAM-1_D1::DBLb3_D4 and ICAM-1_D1-D2::
DBLb3_D4 interactions.
For analysis of DBLb3_D4 mutant binding to 24E9 mAb, 24E9 mAb
was immobilized to 230 RU on a CM5 chip (GE Healthcare) precoupled
with protein G. DBLb3_D4 mutants were diluted into 10 mM HEPES pH
7.2, 300 mM NaCl, and 0.05% Tween 20, and for each mutant a concen-
tration series (31.25, 15.62, 7.81, 3.90, 1.95, and 0.97 nM) was flowed over
the chip surface at 40 ml/min with 240 s association time and 400 s dis-
sociation time. The signal from a flow cell lacking the DBLb3_D4 domain
was subtracted from all measurements. The sensor surface was regenerated
between runs with 100 mM glycine-HCl, pH 2.0 for 120 s at a flow rate of
10 ml/min.
For all measurements, sensorgrams corresponding to at least four dif-
ferent concentrations were globally fitted into a one-site kinetic model,
and the values for ka, kd, and KD were obtained using the BIAevaluation
software 2.0.3 (GE Healthcare).
HDX MS
HDX MS experiments were fully automated using a PAL autosampler
(CTC Analytics). This controlled the start of exchange and quench reac-
tions, proteolysis temperature (4˚C), injection of the deuterated peptides,
management of the injection and washing valves, and triggering of HPLC
pumps and acquisition by the mass spectrometer. A Peltier-cooled box
(4˚C) contained two Rheodyne automated valves (6-port for injection and
10-port for washing), a desalting cartridge (peptide Opti-Trap Micro from
Optimize Technologies), and an HPLC column (C18 Jupiter 4 mm Proteo
90 A˚, 503 1 mm from Phenomenex). HDX MS reactions were carried out
using gel-filtered DBLb3_D4 and DBLb3_D4::24E9 Fab (1:1 molar ra-
tio), both at concentrations of 40 mM. Deuteration was initiated by a 5-fold
dilution of DBLb3_D4 or DBLb3_D4::24E9 Fab (10 ml) with PBS in D2O
(40 ml). The proteins were deuterated for 20 min at 4˚C or 20 min at room
temperature (26˚C). Considering the change of exchange kinetics of amide
hydrogens with temperature (about a 3-fold exchange increase for each
10˚C increase in temperature), the last condition is equivalent to a 200-min
deuteration at 4˚C. A total of 50 ml 0.8 M Tris(2-carboxyethyl)phosphine,
2 M glycine was added for 10 min at 4˚C to quench back-exchange and
to reduce disulphide bridges. The proteins were digested online with
immobilized porcine pepsin (Sigma) and recombinant nepenthesin-1 (28)
proteases. The peptides were desalted using an HPLC pump (Agilent
Technologies) with 0.03% trifluoroacetic acid in water (buffer A) at a flow
rate of 100 ml/min. The peptides were then separated using another HPLC
pump (Agilent Technologies) at 50 ml/min for 6 min with a 15–50%
gradient of buffer B (buffer B: acetonitrile 90%, trifluoroacetic acid 0.03%
in water), followed by 9 min at 50% B and 5 min at 100% B. The peptide
masses were measured using an electrospray-time of flight mass spec-
trometer (Agilent 6210) in the 300–1300 m/z range. The peptides were
previously identified by tandem mass spectrometry, using a Bruker APEX-
Q FTMS (9.4 T). The Mass Hunter (Agilent Technologies) and Data
Analysis (Bruker) software were used for data acquisition. The HD Ex-
aminer software (Sierra Analytics) was used for HDX MS data processing.
For each deuteration time (20 min at 4˚C or 20 min at room temperature),
experiments were performed in triplicate and measurements were aver-
aged.
The Journal of Immunology 3275
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SAXS
SAXS measurements were carried out at the EMBL BioSAXS P12
beamline at the DORIS storage ring, DESY (Hamburg, Germany). Scat-
tering data were recorded at a wavelength of 1.24 A˚ using a two-
dimensional photon counting PILATUS 2 million pixel x-ray detector
(Dectris, Baden, Switzerland). The distance between detector and sample
was 3.1 m, resulting in a q range of 0.01–0.44 A˚21 [q = 4psin(u)l2 1,
where q is the scattering vector, 2u is the scattering angle, and l is the
wavelength].
Samples for SAXS were prepared in buffer containing 20 mM HEPES,
150 mM NaCl, pH 7.4 and purified by size exclusion chromatography.
Sample purity was verified by SDS-PAGE, and only samples with a purity
.95% were used for data collection. Before measurement, samples were
centrifuged at 13,000 rpm for 5 min at 4˚C. For each sample, a concen-
tration series (3.78, 1.79, 0.87, 0.34, 0.18 mg/ml for DBLb3_D4 and 4.64,
2.38, 1.16, 0.59, 0.19 mg/ml for DBLb3_D4::24E9 Fab) was measured at
10˚C. Before and after each sample, buffer was measured as a control.
The scattering curves were manually inspected using PRIMUS (29), and
frames showing signs of radiation damage were omitted in data analysis.
Unaffected frames were averaged for each measurement, and the buffer
signal was subtracted from the sample signal. To eliminate the effects of
potential concentration-dependent protein aggregation at low scattering
angles, the scattering curves of each concentration series were extrapolated
to zero concentration. A composite curve was generated by scaling and
merging the zero concentration curve with data for the highest concen-
tration. The radius of gyration (Rg) was estimated by Guinier analysis
using AutoRg in PRIMUS, whereas the maximum particle diameter (Dmax)
and the pair distance distribution functions Pr were calculated using
GNOM (30).
Ab initio models were generated from solution scattering data by
DAMMIF (31) using default parameters with P1 symmetry. For both
DBLb3_D4 and DBLb3_D4::24E9 Fab, 20 independent DAMMIF models
were averaged using DAMAVER (32). The averaged model was further
refined by DAMMIN (33), using default parameters and the original pair
distance distribution functions as input. SITUS was used to calculate
volumetric representation from the bead models generated by DAMMIN,
and homology models of DBLb3_D4 and a mouse Fab fragment (Protein
Data Bank [PDB] ID 3GK8) were docked into the resulting envelopes
using the program SCULPTOR (34). The DBLb3_D4 homology model
was generated with I-TASSER (c-score 20.9) using the structures of
DBL3X (PDB ID 3BQK), NTS-DBL1a (PDB ID 2XU0), EBA-175 (PDB
ID 1ZRL), and EBA-140 (PDB ID 4GF2) as templates. Structural models
were visualized using PyMol Version 1.5.0.4 (Schro¨dinger).
Results
The 24E9 mAb is cross-reactive against DC4-containing
PfEMP1 present on the surface of IE
We have previously observed that 3D7 PFD1235w DBLb3_D4
elicits adhesion-inhibitory Abs that are cross-reactive to DC4-
containing PfEMP1 from genetically distant parasite isolates
(12). To study the specific epitopes targeted by such protective
Abs in more detail, we first raised a monoclonal mouse Ab against
3D7 PFD1235w DBLb3_D4. This mAb, named 24E9, is of IgG1
isotype with k L chains (data not shown). We tested the reactivity
of 24E9 against native PfEMP1 on the surface of IE by flow
cytometry. Both 24E9 mAb and Fab fragments generated from this
Ab bound to erythrocytes infected with 3D7 parasites expressing
DC4-containing PfEMP1 (Fig. 1). In contrast, 24E9 mAb did not
recognize DC42 3D7 IE.
24E9 mAb showed cross-reactivity to erythrocytes infected with
the heterologous parasite strain BM057 (Fig. 1), which expresses
a DC4 containing PfEMP1. We therefore used ELISA to test
whether 24E9 mAb binds to other DBLb domains. 24E9 mAb
cross-reacted with five DBLb3_D4 domains from DC4 containing
PfEMP1 proteins cloned and expressed from Ghanaian field iso-
lates (12) (Fig. 2A), but not with non-DC4 DBLb domains from
the IT4 isolate (Fig. 2B) or other PfEMP1 domains from the 3D7,
Dd2, or HB3 isolates (Fig. 2C). Therefore, 24E9 mAb can rec-
ognize native PfEMP1 expressed on the surface of IE and shows
patterns of cross-reactivity to DC4-containing PfEMP1s similar to
Abs found in pooled immune plasma from patients infected with
parasites expressing 3D7 PFD1235w (12).
The interaction between DC4 DBLb3_D4 and ICAM-1 is
inhibited by 24E9
Binding to ICAM-1 is mediated through the DBLb3_D4 domains
of DC4 PfEMP1 (12). We therefore tested whether the 24E9
mAb blocks this interaction. We first compared the affinity of
DBLb3_D4 for both 24E9 and ICAM-1 by SPR. We used 24E9
Fab fragments, leading to monovalent binding, which allowed
for global fitting of the data with a one-site binding model. 24E9
Fab bound to DBLb3_D4 with low nanomolar affinity, compa-
rable with the affinity of DBLb3_D4 for ICAM-1_D1-D2 and
ICAM-1_D1 (Fig. 3A, Table I). Furthermore, the interaction
between 24E9 Fab and DBLb3_D4 showed fast association and
slow dissociation rates similar to those observed for the in-
teraction between ICAM-1_D1 and DBLb3_D4 (Fig. 3A–C,
Table I).
We next analyzed whether 24E9 mAb directly inhibits the
DBLb3_D4::ICAM-1 interaction. A chip coupled with DBLb3_D4
was preincubated with different concentrations of 24E9 Fab, fol-
lowed by injection of ICAM-1_D1. As a control, ICAM-1_D1 was
flowed over the chip surface without prior incubation with 24E9 Fab
(Fig. 3D, red curve). Preabsorption of DBLb3_D4 with increasing
concentrations of 24E9 Fab reduced the binding of ICAM-1_D1 in
a concentration-dependent manner (Fig. 3D, 3E), demonstrating that
24E9 Fab effectively blocks the interaction between DBLb3_D4 and
ICAM-1_D1.
The observation that 24E9 is cross-reactive against several DC4
DBLb3_D4 domains from different parasite isolates (Fig. 2)
raised the possibility that 24E9 also cross-inhibits the interaction
between ICAM-1 and these domains. We tested this by ELISA and
found that 24E9 mAb inhibited ICAM-1 binding of PFD1235w
DBLb3_D4 and of the five DC4 DBLb3_D4 domains in a con-
centration-dependent manner (Fig. 3F). Taken together, these data
show that 24E9 mAb is both cross-reactive and cross-inhibitory
of ICAM-1 binding to all tested DC4 DBLb3_D4 domains and
binds with a sufficiently strong affinity to effectively compete with
ICAM-1 binding.
FIGURE 1. DC4-expressing P. falciparum IE are recognized by 24E9
mAb and Fab. PFD1235w DBLb3_D4 mouse anti-sera and 24E9 mAb
were tested by flow cytometry on 3D7 DC4+, BM57 DC4+, and 3D7 DC42
parasite lines. 24E9 Fab was tested only on DC4+ 3D7. IE with antisera,
24E9 mAb, or 24E9 Fab are shown in gray, whereas IE without Abs
(negative controls) are shown in black.
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24E9 mAb and 24E9 Fab inhibits IE binding to ICAM-1 under
flow conditions
IE expressing DC4 PfEMP1 proteins adhere to ICAM-1 (12),
a phenotype linked to sequestration of IE in the microvasculature
of the brain (6, 35). We therefore tested whether the 24E9 Ab
blocks this interaction. Biochips were coated with recombinant
ICAM-1, and 3D7 DC4+ parasites were flowed over at 1 dyn/cm2.
The 24E9 mAb successfully inhibited adhesion at 1 mg/ml (67%;
133 nM) and at 10 mg/ml (79%; 1.3 mM), whereas the control
mouse IgG (10 mg/ml) failed to significantly alter adhesion to
ICAM-1 (Fig. 4A). Fab fragments generated from 24E9 mAb were
also assessed for inhibition at 1 mg/ml (83%; 400 nM) and were
FIGURE 3. 24E9 mAb inhibits ICAM-1 binding of DC4 DBLb3_D4. PFD1235w DBLb3_D4 was coupled to a sensor chip surface (RU = 400). Analytes
were injected at 45 ml/min with an association phase of 120 s and a dissociation phase of 400 s. Shown are sensorgrams for binding of DBLb3_D4 to
ICAM-1_D1-D2 (A), ICAM-1_D1 (B), and 24E9 Fab (C). Data (black lines) are modeled to a one-site model (red lines). (D) Sensorgrams observed for the
sequential binding of 24E9 Fab fragment and ICAM-1_D1 to immobilized PFD1235w DBLb3_D4. Zero response is taken as the start of injection of
ICAM-1_D1. A sensorgram for the binding of ICAM-1_D1 in the absence of 24E9 Fab is shown in red. (E) Quantification of the amount of ICAM-1_D1
binding to PFD1235w DBLb3_D4 after preincubation of the DBLb3_D4 with different concentrations of 24E9 Fab. (F) The ability of 24E9 mAb to inhibit
DC4 DBLb3_D4 domains binding to ICAM-1–Fc as assayed by ELISA. Mouse IgG was added as control. Mean OD values are shown for three inde-
pendent experiments. Error bars indicate SD.
FIGURE 2. 24E9 mAb is cross-
reactive against DC4 DBLb3_D4
domains. 24E9 mAb was tested against
DC4-DBLb3_D4 domains (A), non-
DC4 DBLb domains from the IT4
isolate (B) and non-DC4 domains from
3D7, Dd2, and HB3 isolates (C) using
ELISA. Mean OD values are shown for
three independent experiments. Error
bars indicate SD.
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titrated to determine the extent of activity. The Fab fragment
continued to demonstrate adhesion inhibition at .50% even at
0.001 mg/ml (67%; 400 pM; Fig. 4A), whereas the control mouse
IgG Fab again failed to alter adhesion at the highest concentration
tested (1 mg/ml). A second strain, BM57 DC4+, was assessed, and
like 3D7 DC4+, adhesion was significantly inhibited by 24E9 mAb
(0.1 mg/ml; 80% inhibition) and 24E9 Fab (0.001 mg/ml; 83%
inhibition) at the lowest concentrations tested (Fig. 4B). The
specificity of adhesion to rICAM-1 was verified by preincubating
control channels with anti–ICAM-1, which significantly reduced
adhesion (81% inhibition; Fig. 4).
24E9 mAb recognizes a conformational epitope
To determine whether 24E9 mAb interacts with a conformational
epitope, we used Western blotting to test the reactivity of 24E9
mAb to reduced and nonreduced DBLb3_D4. As a control, we
performed the same experiment with the non-DC4 PFD1235w
DBLb3_D5 domain. 24E9 recognized only nonreduced DBLb3_D4
(Fig. 5A). We observed the same result by ELISA (Fig. 5B), where
24E9 recognized only nonreduced DBLb3_D4. To test whether
the loss of reactivity of the mAb toward DTT-treated PFD1235W
DBLb3_D4 was a result of the mAb being reduced in the ELISA,
we performed the same assay using the PFD1235w DBLg-specific
human mAb (AB01), which is only partially dependent on the
correct folding of DBLg (24). AB01 mAb was still able to rec-
ognize DTT-treated DBLg (Fig. 5C) showing that a similar mAb
remained intact in the ELISA. This suggests that 24E9 mAb tar-
gets a conformational epitope.
The epitope targeted by 24E9 partially overlaps with the
potential ICAM-1 binding site of PFD1235w DBLb3_D4
To identify the specific peptides and surface features recognized
by 24E9, we used HDX MS, a powerful, modern immunological
method to examine epitopes bound by Abs under native conditions
(36, 37). We analyzed the DBLb3_D4::24E9 Fab complex by
measuring deuterium uptake over 200 min deuteration time for 83
partly overlapping peptides from DBLb3_D4, alone or in complex
with 24E9 Fab. These correspond to 79% of the DBLb3_D4
Table I. Kinetic parameters derived from SPR experiments on ICAM-1_D1-D2, ICAM-1_D1, and 24E9 mAb interacting with
PFD1235w DBLb3_D4
Interaction ka (310
5 M21 s1) kd (310
24 s21) KD (nM) Model
ICAM-1_D1-D2::DBLb3_D4 2.12 16.74 7.90 One-site
ICAM-1_D1::DBLb3_D4 14.4 33.73 2.34 One-site
24E9 Fab::DBLb3_D4 2.25 7.58 3.37 One-site
FIGURE 4. 24E9 mAb and 24E9 Fab inhibit IE
binding to ICAM-1 under flow conditions. Inhibition of
adhesion by 24E9 mAb and 24E9 Fab of 3D7 DC4+
(A) and BM57 DC4+ (B) to rICAM-1 coated onto
Biochips. Abs were titrated at 0.1–10 mg/ml (24E9
mAb) and 0.001–1 mg/ml (24E9 Fab). Each condition
was run in triplicate for a minimum of three indepen-
dent experiments and expressed as average number
bound per square millimeter compared with untreated
controls. Mouse IgG and mouse IgG Fab fragments
were added as controls. Statistical significance was
determined via one-way ANOVA with Tukey’s multi-
ple comparison test. **p , 0.05, ***p = 0.0001.
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primary sequence (Fig. 6A). Comparison of the level of deutera-
tion highlighted three distinct regions, P1, P2, and P3, which show
a reduction in deuterium uptake in the complex with 24E9 when
compared with that of free DBLb3_D4 (Fig. 6A), indicating that
these regions are masked by 24E9 Fab. Similar results were also
observed for 20 min deuteration time (data not shown). P1 is lo-
cated in the N-terminal third of DBLb3_D4 (subdomain 1), P2 in
the center region (subdomain 2), whereas P3 is near the C ter-
FIGURE 5. 24E9 mAb recognizes a conformation epitope on PFD1235w DBLb3_D4. (A) Western blotting of PFD1235w DBLb3_D4 (D4) and
DBLb3_D5 (D5). +DTT (reduced), 2DTT (nonreduced). Lane 1, Prosieve protein marker (M) visualized by phosphorescent paint as dots. Lanes 2 and 3,
DBLb_D4 (6DTT). Lanes 4 and 5, DBLb3_D5 (6DTT). Arrow shows nonreduced DBLb3_D4 (lane 3) recognized by 24E9 mAb. (B) 24E9 mAb ELISA
reactivity against reduced (+DTT) and nonreduced (2DTT) PFD1235w DBLb3_D4. (C) AB01 mAb ELISA reactivity against reduced (+DTT) and
nonreduced (2DTT) DBLg of PFD1235w. Mean OD values are shown for three independent experiments. Error bars indicate SD.
FIGURE 6. The 24E9 Fab binds to the convex surface of PFD1235w DBLb3_D4. (A) Peptides from DBLb3_D4 that were identified in mass spectra are
represented by bars overlaying the primary sequence. The secondary structure, derived from a homology model of DBLb3_D4, is shown below the se-
quence. The level of protection of individual peptides, as determined by comparing the %D incorporation over 200 min for free DBLb3_D4 with that for
DBLb3_D4 bound to 24E9 Fab, is color coded according to the scale bar. Highly protected areas are in red, whereas unprotected areas are in gray. Three
highly protected regions were P1 (residues 110–121), P2 (193–220), and P3 (357–388), as indicated. (B) HDX MX results were mapped onto a model of the
PFD1235w DBLb3_D4 domain. Protected areas are color coded as shown in (A). (C) Surface of PFD1235w DBLb3_D4 model as shown in (B). (D)
Potential ICAM-1 binding sites on the DBLb3_D4 model as predicted by Bertonati and Tramontano (18) (green) and determined by Bengtsson et al. (12)
(light green).
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minus of the protein and part of subdomain 3. When mapped on
a homology model of DBLb3_D4, all three regions cluster to
a well-defined, surface-exposed area (Fig. 6B, 6C), in accordance
with the observation that 24E9 targets a conformational epitope
(Fig. 5A–C). The size of this protected area is 2887 A˚2, which is
comparable with the total ∼2800 A˚2 surface-exposed area of the
variable loops of a Fab fragment.
The area protected by 24E9 Fab lies on the convex surface of
DBLb3_D4. Mutational and modeling studies of non-DC4 DBLb
domains previously showed that this surface contains the ICAM-1
binding site (18–20, 38). Amino acids equivalent to residues im-
portant for the interaction between group B DBLb domains and
ICAM-1 (Fig. 6D, dark green) (18) partly overlap with P1, P2, and
P3. Furthermore, the ICAM-1 binding site of DBLb3_D4 has
been mapped to the C-terminal third of the domain (Fig. 6D, light
green) (12). This includes region P3, which shows the strongest
protection from deuteration in the DBLb3_D4::24E9 Fab com-
plex. These observations indicate that the epitopes targeted by
24E9 overlap with the ICAM-1 binding site of DBLb3_D4.
To identify which of the protected peptides of DBLb3_D4
makes the most significant contribution to the binding affinity,
we first compared the P1, P2, and P3 regions between DBLb3
domains that are recognized by 24E9 and those that are not
(Fig. 7A). This revealed two motifs, P2b and P3a, which are
mostly conserved only among 24E9 binding DBLb3 domains
(Fig. 7A) and are strongly protected in the DBLb3_D4::24E9 Fab
complex, suggesting that these motifs might directly contribute to
24E9 binding. To test this, we generated mutants by swapping the
P2b and P3a peptides from DBLb3_D4 for the equivalent regions
of the DBLb3_D5 domain (Fig. 7B), which is not recognized
by 24E9. These mutants were expressed and purified as native
DBLb3_D4, and their folding was confirmed by CD spectroscopy
(Supplemental Fig. 1). The binding of the mutants to 24E9 mAb
was analyzed by SPR, which showed that the exchange of the P2b
peptide had little effect on 24E9 affinity, whereas exchange of the
P3a led to a complete loss of Ab binding (Fig. 7C, Table II). This
demonstrates that P2 makes a minor contribution to 24E9 binding,
whereas the P3 region contains an essential determinant of Ab
binding.
Low-resolution structure of the DBLb3_D4::24E9 Fab
complex
To understand better the architecture of the DBLb3_D4::ICAM-1
complex, we performed small-angle x-ray scattering analysis of
the DBLb3_D4 domain alone or in complex with 24E9 Fab
(Fig. 8). The Rg determined from the composite scattering curve
(Fig. 8A) was higher for the DBLb3_D4::24E9 Fab complex than
for DBLb3_D4 alone (Table III). The increased Porod volume and
FIGURE 7. Fine mapping of the 24E9 binding site on DBLb3_D4. (A) Sequence conservation of P1, P2, and P3 among DBLb domains. Sequences were
aligned with MUSCLE. The ability of the DBLb domains to bind to 24E9 is indicated. (B) PFD1235w DBLb3_D4 mutants were generated to determine the
importance of protected peptides in the 24E9 mAb binding site. (C) SPR analysis of 24E9 mAb binding site mutants. 24E9 mAb was immobilized to 230
RU on a CM5 chip precoupled with protein G. Analytes were flowed over the chip surface at 40 ml/min with 240 s association and 400 s dissociation times.
Data (black curves) were fitted to a one-site model (red curves).
Table II. Kinetic parameters derived from SPR experiments on 24E9 mAb interacting with mutant version of PFD1235w DBLb3_D4
Interaction ka (310
7 M21 s21) kd (310
25 s21) KD (pM) Rmax (RU) Model
DBLb3_D4 wild type::24E9 mAb 6.4 7.7 1.2 229.2 One-site
DBLb3_D4_P2b_D5::24E9 mAb 1.87 4.1 2.19 239.2 One-site
DBLb3_D4_P3a_D5::24E9 mAb 2.2 24 110 8.64 One-site
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the apparent molecular mass were also consistent with formation
of a 1:1 complex between 24E9 Fab and DBLb3_D4 (Table III).
The distance distribution function shows a more skewed profile for
DBLb3_D4::24E9 Fab than that for DBLb3_D4 alone (Fig. 8B),
indicating that binding of 24E9 Fab results in a more elongated
particle (39). Accordingly, the Dmax increases from 9.4 nm for
DBLb3_D4 to 12.2 nm for the complex (Table III).
Envelopes for DBLb3_D4 and DBLb3_D4::24E9 Fab were
generated by ab initio modeling based on the scattering data, and
the homology model of DBLb3_D4 was manually docked into
these envelopes together with a model Fab fragment. Comparison
of the two envelopes reveals that the DBLb3_D4:24E9 Fab
complex is more elongated, with an additional mass protruding
from DBLb3_D4, corresponding to 24E9 Fab (Fig. 8C, 8D). Si-
multaneous docking into this envelope positions the Ag binding
loops of the Fab toward the regions identified as 24E9 binding site
by HDX MS analysis (Figs. 6, 8D). This low-resolution shape
reconstruction further supports the conclusion that 24E9 targets
the convex surface of DBLb3_D4 and overlaps with its potential
ICAM-1 binding site.
Discussion
The presence of inhibitory Abs that bind to the variable surface Ag
PfEMP1 correlates with naturally acquired, protective immunity
against PfEMP1-mediated IE adhesion during severe malaria (38,
40, 41). However, the epitopes targeted by such functional Abs
and the mechanism by which they prevent IE adhesion are still
unknown. In this study, we used immunological and biophysical
methods to demonstrate that an mAb raised against a single DC4
DBLb domain recognizes epitopes conserved between DC4
DBLb domains and prevents ICAM-1 binding by both purified
domains and IE, occluding the ICAM-1 binding site on the surface
of a DBLb domain.
Of biological relevance, the 24E9 mAb and Fab fragments in-
hibit 3D7 DC4+ IE at picomolar to subnanomolar concentrations
under physiological flow conditions (Fig. 4). Titration of the Abs
not only confirmed the specificity of 24E9, but also illustrated how
effective the Ab remained at low concentrations. Despite having
only one Ag binding site, the 24E9 Fab is a more potent inhibitor
of ICAM-1 binding than 24E9 mAb (Fig. 4A). This lower efficacy
of the full-length and thus bulkier IgG molecule might be explained
by steric hindrance and partially restricted access to the binding site
of the native PfEMP1 as compared with the smaller Fab fragment.
24E9 also successfully inhibited the ICAM-1 adhesion of erythro-
cytes infected by a genetically distinct parasite, BM57 DC4+. The
mAb 24E9 is therefore able to inhibit ICAM-1 binding of DC4
DBLb3_D4 domains from a number of different parasite isolates,
indicating that these domains share a common antigenic epitope.
FIGURE 8. Molecular architecture of the PFD1235w DBLb3_D4:24E9 Fab complex. (A) Theoretical scattering curves derived from ab initio models
(solid lines) of DBLb3_D4 and DBLb3_D4::24E9 Fab superimposed on the experimental scattering data (circles). (B) Normalized distance distribution
function P(r) for DBLb3_D4 and DBLb3_D4::24E9 Fab. (C and D) The homology model of DBLb3_D4 was docked into ab initio envelopes of (C)
DBLb3_D4 alone and (D) the DBLb3_D4::24E9 Fab complex. The peptides identified as being protected in the DBLb3_D4::24E9 Fab complex are color
coded as in Fig. 5. The structure of a mouse Fab fragment (green, PDB ID 3GK8) was used as a model for 24E9 Fab.
Table III. Experimental values derived from PFD1235w DBLb3_D4::24E9 Fab SAXS experiments
Rgexp (nm) Dmax (nm) Vporod (nm
3) Mrexp (kDa) Mrapp (kDa) x
DBLb3_D4 2.69 9.39 91.13 55 54.45 4.57
DBLb3_D4::24E9 Fab 3.81 12.16 140.17 105 91.05 3.456
The experimental Rg (Rgexp) was determined using AutoRG (8), the Dmax was derived from GNOM (30), and the Porod volume (Vporod) was determined by using PRIMUS
(29). The expected molecular mass (Mrexp) is shown for DBLb3_D4 and the DBLb3_D4::24E9 complex. The apparent molecular mass (Mrapp) was calculated from the
volume excluded in the final DAMMIN (33) model divided by 2. The x value represents the best fit of 20 low-resolution shape reconstructions using ab initio modeling.
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Using HDX MS, we have identified three regions that cluster on
the convex surface of PFD1235W DBLb3_D4 and that show re-
duced hydrogen-deuterium exchange in the presence of 24E9. One
of these three peptides, the P3a motif of region P3, was protected
most strongly (Fig. 6) and is absolutely required for Ab binding
(Fig. 7C). Indeed, this motif is strictly conserved only among
DBLb3 domains recognized by 24E9. In addition, the P2b motif
of region P2 is conserved in most 24E9-binding DBLb3 domains,
but varies significantly between nonbinders (Fig. 7A). However,
this motif plays only a minor role in 24E9 binding, as demon-
strated by a slight reduction in KD when it is mutated (Table II). In
contrast, P1 and the remaining regions of P2 and P3 show a sub-
stantial degree of conservation between both 24E9-binding and
nonbinding DBLb domains (Fig. 7A), making it more likely that
these amino acids are not part of the 24E9-binding site, but instead
are sterically protected from hydrogen-deuterium exchange by the
presence of the Ab binding to the neighboring epitopes. Our
mapping data also suggest a mechanism by which 24E9 inhibits
ICAM-1 binding, because epitopes recognized by mAb 24E9
cluster on the convex surface of DBLb3_D4 that is predicted to
contain the binding site for ICAM-1 (15, 19, 20, 38). In addition,
region P3, which contains the main determinant of 24E9 binding,
lies within subdomain 3 of DBLb3_D4. This subdomain forms
a significant part of the convex surface of DBLb3_D4, and
a previous study suggested that it is required for the interaction
with ICAM-1 (12). These findings indicate that 24E9 exerts its
inhibitory function by masking the ICAM-1 binding site of
DBLb3_D4. These conclusions are further supported by our low-
resolution shape reconstruction, determined by SAXS, which
shows that 24E9 Fab adopts an orientation relative to the
DBLb3_D4 that is similar to that of ICAM-1_D1-D2 bound to the
DBLb domain of IT4var13 (19).
The identification of the convex surface of DBLb domains as
the main target of inhibitory Abs provides important knowledge
for choosing the components of a vaccine aimed at preventing
PfEMP1-mediated adhesion of IE during severe malaria. A de-
tailed mapping and structural characterization of the ICAM-1
binding sites of DBLb domains from group A and B PfEMP1
and the identification of conserved surface features involved in
this interaction are now needed to guide future decisions about
how to design immunogens that elicit Abs inhibitory of ICAM-1
binding. Our observation that an Ab raised against a single
DBLb3_D4 domain prevents the interaction between ICAM-1 and
DBLb3_D4 domains from genetically distant parasite isolates
demonstrates the existence of conserved antigenic epitopes. These
might be used to specifically induce the production of Abs that
cross-inhibit ICAM-1 binding by an important set of ICAM-1
binding DBLb domains. Because DC4 DBLb3_D4 domains are
found in group A PfEMP1, which have been associated with in-
creased IE adhesion and severe malaria (6, 15, 42), such conserved
epitopes are promising candidates for inclusion in a vaccine that
interferes with the PfEMP1::ICAM-1 interaction and confers
strain-independent protection against severe malaria.
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